Prognostic significance of ¹⁸F-FDG PET/CT parameters in soft tissue sarcoma: a systematic review and meta-analysis.

IF 3.5 2区医学 Q2 ONCOLOGY

Cancer Imaging Pub Date : 2025-07-29 DOI:10.1186/s40644-025-00912-x

Shaoli Li, Rui Bai, Hui Wang, Qunan Sun, Guannan Wang, Sujing Jiang, Ying Dong

{"title":"Prognostic significance of 18F-FDG PET/CT parameters in soft tissue sarcoma: a systematic review and meta-analysis.","authors":"Shaoli Li, Rui Bai, Hui Wang, Qunan Sun, Guannan Wang, Sujing Jiang, Ying Dong","doi":"10.1186/s40644-025-00912-x","DOIUrl":null,"url":null,"abstract":"Background: The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) parameters to predict prognosis for patients with soft tissue sarcoma (STS) remains controversial.Objectives: This meta-analysis aimed to systematically evaluate the prognostic significance of 18F-FDG PET/CT parameters in STS.Design: This study is a systematic review and meta-analysis.Data sources and methods: A literature search was conducted in PubMed, Embase, and the Cochrane Library for relevant studies up to January 1st, 2024. Studies exploring the association of maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) with overall survival (OS) and progression-free survival (PFS) in STS were included. Pooled hazard ratio (HR) with 95% confidence interval (CI) was calculated using random-effects models.Results: Nineteen studies with 962 patients were included in our meta-analysis. Among these, 16 studies evaluated the correlation between the SUVmax and OS, 10 studies assessed the relationship between MTV and OS, 9 studies examined the association of TLG with OS, and 8 studies investigated the prognostic value of SUVmax in relation to PFS. The pooled HRs of SUVmax, MTV, and TLG for OS were 1.17 (95% CI: 1.07-1.27),1.87 (95% CI: 1.16-3.03), and 2.00 (95% CI: 0.99-4.01), respectively. For PFS, the pooled HR of SUVmax was1.62 (95% CI: 1.14-2.31).Conclusion: This meta-analysis indicates that the metabolic parameter SUVmax derived from 18F-FDG PET/CT is significantly associated with poor prognosis in STS, for both OS and PFS. Additionally, MTV was significantly correlated with poor OS, whereas TLG did not show a significant relationship with prognosis in patients with STS.","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"25 1","pages":"94"},"PeriodicalIF":3.5000,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308899/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40644-025-00912-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The role of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) parameters to predict prognosis for patients with soft tissue sarcoma (STS) remains controversial.

Objectives: This meta-analysis aimed to systematically evaluate the prognostic significance of ¹⁸F-FDG PET/CT parameters in STS.

Design: This study is a systematic review and meta-analysis.

Data sources and methods: A literature search was conducted in PubMed, Embase, and the Cochrane Library for relevant studies up to January 1st, 2024. Studies exploring the association of maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) with overall survival (OS) and progression-free survival (PFS) in STS were included. Pooled hazard ratio (HR) with 95% confidence interval (CI) was calculated using random-effects models.

Results: Nineteen studies with 962 patients were included in our meta-analysis. Among these, 16 studies evaluated the correlation between the SUVmax and OS, 10 studies assessed the relationship between MTV and OS, 9 studies examined the association of TLG with OS, and 8 studies investigated the prognostic value of SUVmax in relation to PFS. The pooled HRs of SUVmax, MTV, and TLG for OS were 1.17 (95% CI: 1.07-1.27),1.87 (95% CI: 1.16-3.03), and 2.00 (95% CI: 0.99-4.01), respectively. For PFS, the pooled HR of SUVmax was1.62 (95% CI: 1.14-2.31).

Conclusion: This meta-analysis indicates that the metabolic parameter SUVmax derived from ¹⁸F-FDG PET/CT is significantly associated with poor prognosis in STS, for both OS and PFS. Additionally, MTV was significantly correlated with poor OS, whereas TLG did not show a significant relationship with prognosis in patients with STS.

查看原文本刊更多论文

18F-FDG PET/CT参数在软组织肉瘤中的预后意义：一项系统综述和荟萃分析

背景：18f -氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（18F-FDG PET/CT）参数在预测软组织肉瘤（STS）患者预后中的作用仍存在争议。目的：本荟萃分析旨在系统评估18F-FDG PET/CT参数在STS中的预后意义。设计：本研究采用系统综述和荟萃分析。数据来源和方法：在PubMed、Embase、Cochrane Library检索截至2024年1月1日的相关研究文献。研究探讨了最大标准化摄取值（SUVmax）、代谢肿瘤体积（MTV）和病变总糖酵解（TLG）与STS总生存期（OS）和无进展生存期（PFS）之间的关系。采用随机效应模型计算合并风险比（HR）和95%置信区间（CI）。结果：我们的荟萃分析纳入了19项研究，共962例患者。其中，16项研究评价了SUVmax与OS的相关性，10项研究评价了MTV与OS的关系，9项研究考察了TLG与OS的相关性，8项研究探讨了SUVmax与PFS的预后价值。SUVmax、MTV和TLG对OS的合并hr分别为1.17 （95% CI: 1.07-1.27）、1.87 （95% CI: 1.16-3.03）和2.00 （95% CI: 0.99-4.01）。对于PFS， SUVmax的合并HR为1.62 （95% CI: 1.14-2.31）。结论：本荟萃分析表明，18F-FDG PET/CT得出的代谢参数SUVmax与STS的不良预后显著相关，无论是OS还是PFS。此外，MTV与不良OS显著相关，而TLG与STS患者预后无显著关系。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Imaging ONCOLOGY-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

CiteScore

7.00

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Cancer Imaging is an open access, peer-reviewed journal publishing original articles, reviews and editorials written by expert international radiologists working in oncology. The journal encompasses CT, MR, PET, ultrasound, radionuclide and multimodal imaging in all kinds of malignant tumours, plus new developments, techniques and innovations. Topics of interest include: Breast Imaging Chest Complications of treatment Ear, Nose & Throat Gastrointestinal Hepatobiliary & Pancreatic Imaging biomarkers Interventional Lymphoma Measurement of tumour response Molecular functional imaging Musculoskeletal Neuro oncology Nuclear Medicine Paediatric.